Fidelity Investments’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.03B | Sell |
30,258,016
-2,874,779
| -9% | -$95.7M | 0.04% | 311 |
|
|
2026
Q1 | $998M | Buy |
33,132,795
+4,117,813
| +14% | +$132M | 0.05% | 296 |
|
|
2025
Q4 | $906M | Buy |
29,014,982
+4,373,620
| +18% | +$108M | 0.05% | 326 |
|
|
2025
Q3 | $498M | Sell |
24,641,362
-33,494,254
| -58% | -$588M | 0.03% | 502 |
|
|
2025
Q2 | $974M | Sell |
58,135,616
-24,606,400
| -30% | -$397M | 0.05% | 283 |
|
|
2025
Q1 | $1.27B | Buy |
82,742,016
+758,785
| +0.9% | +$13.6M | 0.08% | 204 |
|
|
2024
Q4 | $1.81B | Buy |
81,983,231
+19,242,468
| +31% | +$350M | 0.11% | 142 |
|
|
2024
Q3 | $1.13B | Buy |
62,740,763
+20,762,226
| +49% | +$363M | 0.07% | 240 |
|
|
2024
Q2 | $682M | Buy |
41,978,537
+20,730,130
| +98% | +$319M | 0.04% | 343 |
|
|
2024
Q1 | $300M | Buy |
21,248,407
+18,523,048
| +680% | +$233M | 0.02% | 626 |
|
|
2023
Q4 | $28.5M | Buy |
2,725,359
+161,020
| +6% | +$1.5M | ﹤0.01% | 1493 |
|
|
2023
Q3 | $26.2M | Buy |
2,564,339
+2,494,156
| +3,554% | +$23.2M | ﹤0.01% | 1481 |
|
|
2023
Q2 | $528K | Sell |
70,183
-74,473
| -51% | -$604K | ﹤0.01% | 2640 |
|
|
2023
Q1 | $1.28M | Buy |
144,656
+972
| +0.7% | +$9.61K | ﹤0.01% | 2470 |
|
|
2022
Q4 | $1.31M | Buy |
143,684
+53,978
| +60% | +$471K | ﹤0.01% | 2480 |
|
|
2022
Q3 | $724K | Sell |
89,706
-18,617
| -17% | -$165K | ﹤0.01% | 2680 |
|
|
2022
Q2 | $815K | Buy |
108,323
+49,182
| +83% | +$428K | ﹤0.01% | 2727 |
|
|
2022
Q1 | $555K | Sell |
59,141
-62,921
| -52% | -$525K | ﹤0.01% | 2952 |
|
|
2021
Q4 | $978K | Buy |
122,062
+69,427
| +132% | +$627K | ﹤0.01% | 2691 |
|
|
2021
Q3 | $513K | Buy |
52,635
+7,150
| +16% | +$67K | ﹤0.01% | 2789 |
|
|
2021
Q2 | $450K | Sell |
45,485
-3,543
| -7% | -$37.5K | ﹤0.01% | 2785 |
|
|
2021
Q1 | $566K | Buy |
49,028
+5,005
| +11% | +$57.4K | ﹤0.01% | 2667 |
|
|
2020
Q4 | $425K | Buy |
44,023
+13,267
| +43% | +$127K | ﹤0.01% | 2675 |
|
|
2020
Q3 | $277K | Sell |
30,756
-8,141,989
| -100% | -$86.1M | ﹤0.01% | 2652 |
|
|
2020
Q2 | $101M | Buy |
8,172,745
+7,019,822
| +609% | +$79.4M | 0.01% | 868 |
|
|
2020
Q1 | $10.4M | Buy |
1,152,923
+459,239
| +66% | +$4.7M | ﹤0.01% | 1680 |
|
|
2019
Q4 | $6.8M | Sell |
693,684
-209,727
| -23% | -$1.87M | ﹤0.01% | 1973 |
|
|
2019
Q3 | $6.22M | Sell |
903,411
-5,192,953
| -85% | -$39.8M | ﹤0.01% | 1983 |
|
|
2019
Q2 | $56.3M | Sell |
6,096,364
-10,968,226
| -64% | -$132M | 0.01% | 1163 |
|
|
2019
Q1 | $268M | Sell |
17,064,590
-18,184,075
| -52% | -$321M | 0.03% | 542 |
|
|
2018
Q4 | $544M | Buy |
35,248,665
+10,766,729
| +44% | +$221M | 0.07% | 260 |
|
|
2018
Q3 | $527M | Buy |
24,481,936
+3,921,785
| +19% | +$91M | 0.06% | 315 |
|
|
2018
Q2 | $500M | Sell |
20,560,151
-1,953,820
| -9% | -$39.8M | 0.06% | 320 |
|
|
2018
Q1 | $385M | Sell |
22,513,971
-2,146,183
| -9% | -$41.9M | 0.05% | 416 |
|
|
2017
Q4 | $467M | Sell |
24,660,154
-1,444,706
| -6% | -$21.7M | 0.05% | 371 |
|
|
2017
Q3 | $459M | Sell |
26,104,860
-16,740,119
| -39% | -$377M | 0.06% | 358 |
|
|
2017
Q2 | $1.42B | Buy |
42,844,979
+6,115,853
| +17% | +$189M | 0.18% | 110 |
|
|
2017
Q1 | $1.18B | Sell |
36,729,126
-26,276,489
| -42% | -$897M | 0.15% | 136 |
|
|
2016
Q4 | $2.28B | Sell |
63,005,615
-4,550,472
| -7% | -$182M | 0.31% | 63 |
|
|
2016
Q3 | $3.11B | Sell |
67,556,087
-794,371
| -1% | -$41.4M | 0.41% | 41 |
|
|
2016
Q2 | $3.43B | Sell |
68,350,458
-9,586,398
| -12% | -$510M | 0.47% | 39 |
|
|
2016
Q1 | $4.17B | Sell |
77,936,856
-7,391,035
| -9% | -$434M | 0.58% | 26 |
|
|
2015
Q4 | $5.6B | Buy |
85,327,891
+12,481,459
| +17% | +$771M | 0.75% | 17 |
|
|
2015
Q3 | $4.11B | Buy |
72,846,432
+7,852,764
| +12% | +$509M | 0.59% | 25 |
|
|
2015
Q2 | $3.84B | Buy |
64,993,668
+8,918,008
| +16% | +$550M | 0.49% | 29 |
|
|
2015
Q1 | $3.49B | Buy |
56,075,660
+9,032,830
| +19% | +$525M | 0.45% | 34 |
|
|
2014
Q4 | $2.71B | Buy |
47,042,830
+7,104,441
| +18% | +$396M | 0.35% | 48 |
|
|
2014
Q3 | $2.15B | Buy |
39,938,389
+191,292
| +0.5% | +$10.1M | 0.29% | 67 |
|
|
2014
Q2 | $2.08B | Buy |
39,747,097
+12,733,185
| +47% | +$651M | 0.28% | 68 |
|
|
2014
Q1 | $1.43B | Buy |
27,013,912
+17,601,258
| +187% | +$813M | 0.2% | 100 |
|
|
2013
Q4 | $377M | Buy |
9,412,654
+742,053
| +9% | +$29.2M | 0.05% | 381 |
|
|
2013
Q3 | $328M | Buy |
8,670,601
+5,385,512
| +164% | +$210M | 0.05% | 421 |
|
|
2013
Q2 | $129M | Buy |
+3,285,089
| New | +$128M | 0.02% | 796 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Fidelity Investments's TEVA Position: Q2 2026 in Review
Fidelity Investments reduced its Teva Pharmaceuticals (TEVA) stake by 8.7% in Q2 2026, selling an estimated $95.7M and leaving 30,258,016 shares worth $1.03B. The position accounts for 0.04% of the portfolio, ranked #311.
Fidelity Investments first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.6B in Q4 2015. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Fidelity Investments held 30,258,016 shares of Teva Pharmaceuticals worth $1.03B as of Q2 2026.
- Fidelity Investments sold 2,874,779 Teva Pharmaceuticals shares in Q2 2026, an estimated $95.7M.
- Teva Pharmaceuticals made up 0.04% of Fidelity Investments's portfolio in Q2 2026, its #311 holding.
- Fidelity Investments first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Fidelity Investments's Teva Pharmaceuticals position peaked at $5.6B in Q4 2015.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.